ICO & IMNP

iCo Therapeutics Inc.(ICO) is a company focused on redosing or reformulating drug candidates with clinical history for new or expanded indications. They take drugs already in use but near or off patent and testt hem through phase 1 and 2 trial testing. They have partnered with Immune Pharmaceuticals Inc (IMNP). is a clinical stage biopharmaceutical company specializing in the development and commercialization of targeted therapeutics, including monoclonal antibodies, or mAbs, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer.

This marriage is going to produce and is so well received the IMNP rang the closing bell at the NASDAQ. IMNP presented at the following two conferences this week:

Marcum Microcap Conference, May 28, 2015 at the Grand Hyatt New York. The flew to the Sachs Immuno-Oncology BD&L and Investment Forum in Chicago, May 29, 2015 at the Hyatt Chicago Magnificent Mile.

At the Marcum Conference, Dr. Daniel Teper, CEO of Immune, will provided a strategic, financial and operational update for investors.

During the Sachs Immuno-Oncology BD&L and Investment Forum, Dr. Teper will discussed the development and partnering strategy for NanomAbs, its antibody nanoparticle conjugate platform for the targeted delivery of chemotherapeutics. Immune recently announced a partnership with STC Biologics for the development of anti-HER2 paclitaxel NanomAbs as well as other development candidates leveraging additional chemotherapeutics and monoclonal antibodies.

Both presentations are available http://www.immunepharmaceuticals.com/

ICO Therapeutics will receive a 32 million pay out or be bought out. This is common knowledge and old news what is not common knowledge is the date of the payment. The trial runs for 6 weeks and judging by the fanfair already it is seen as a sure thing by Immune that it will be a success. I don't always follow the hype I will have an eye on this but no position.